
First Came Ozempic Face. Now People Are Dealing With Ozempic Hair and Muscle Loss
Now, people are noticing that Ozempic and similar GLP-1 drugs (Mounjaro, Wegovy, Rybelsus, and Zepound, to name a few) are affecting their hairline and possibly weakening their muscle strength. So what gives?
Why is this happening?
Though some studies link these drugs to hair loss, experts still say it is not a direct side effect of GLP-1s like Ozempic or other medications like Mounjaro. Marisa Garshick, MD, board-certified dermatologist at MDCS Dermatology, explains that it's actually more of an indirect result of rapid weight loss, nutritional deficiencies, or stress on the body. 'Telogen effluvium is a type of hair shedding that may be noticed a few months after the body experiences some type of change or stress,' says Dr. Garshick (it's akin to the dramatic hair shedding some saw in the months post-COVID-19). 'People on GLP-1s may not actually notice hair shedding or thinning for several months after they are on it.'
As for muscle loss—that's just a general side effect of losing weight, regardless of whether the impetus is diet, exercise, surgery, or a medication like Ozempic. Holly Lofton, MD, director of the medical weight management program at NYU Langone Health, tells Vogue that experts see medications like Wegovy and Zepbound are causing the same—and sometimes more—amount of muscle loss as one might experience through more traditional weight loss methods. Studies show that 25 to 30% of the total weight loss caused by calorie restriction and exercise comes from lean body mass, which includes muscles. So if someone were to lose 20 pounds, she says around 5 to 6 pounds of that might be muscle that is lost. Studies on medications like Wegovy and Zepbound show patients can lose roughly 15 to 22% of their total weight, with about 25% of that weight loss being lean muscle mass. 'These drugs are not necessarily muscle-sparing,' she says. 'However, because people tend to lose more total weight on these medications, the absolute amount of muscle loss can be greater (unless we intervene with resistance training and adequate protein intake).'
What can you do about it?
There are a few things you can do to treat hair and muscle loss that you might experience when on these medications. Dr. Garshick says that it is normal to shed about 50 to 100 hairs a day, so you should only be concerned if you notice significantly more hair falling out or if your hair loss persists longer than three to six months. If that is the case, she recommends seeing a board-certified dermatologist to be properly evaluated. 'Since telogen effluvium is considered a temporary process, once the weight stabilizes, it is possible the hair loss will slow down and hair regrowth will resume and normalize even without doing any specific intervention,' she says. 'While this process can take six to 12 months, providing reassurance that it can get better on its own is often sufficient.'
She says getting bloodwork done to see if there are hormonal changes or nutritional deficiencies that can be addressed through diet (making sure you are consuming enough protein is key) or the use of oral supplements like Nutrafol or Wellbell. You can also turn to thickening and volumizing shampoos, like the Nioxin Hair Fall Defense Shampoo or the Vegamour GRO Revitalizing Shampoo, and leave-in products like the Virtue Flourish Density Booster, to help increase hair density. For more intense treatments, you can inquire about platelet-rich plasma (PRP) therapy to stimulate hair growth.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


San Francisco Chronicle
33 minutes ago
- San Francisco Chronicle
In the age of Ozempic, is there still a role for weight-loss surgery?
As weight-loss medications like Ozempic exploded across the U.S. over the past four years, bariatric surgeons faced a bit of an existential crisis: Were their jobs about to become obsolete? For the first time, health care providers have a combination of highly effective therapies to offer patients with obesity, a condition that has long been one of the most difficult to treat. The outlook is especially exciting for patients who are severely overweight — including those who are considered too heavy for surgery. Indeed, there may exist a future where drugs and other interventions prevent people from ever becoming obese and needing weight-loss surgery. But that future is far off, say surgeons and other weight-loss experts. In fact, even as millions of Americans are now taking drugs that dramatically improve weight loss, surgeons say their tool may be more powerful than ever. 'A massive amount of people have tried these medications, so the question becomes: 'How well do they work and is there a role for bariatric surgery in the era of these drugs?'' said Dr. Jonathan Carter, a UCSF surgeon who specializes in minimally invasive procedures. Bariatric surgery has for decades been the most effective and durable weight-loss tool available. The specific procedures vary, but the most common operation now is the gastric sleeve surgery, in which a large portion of the stomach is removed. Roughly a quarter of a million Americans undergo a bariatric procedure each year. The surgeries are highly effective for weight loss — patients can lose about a third of their body weight within two years, and they generally keep off most of those pounds long-term. The side effects with the sleeve procedure are minimal and may include gas, bloating and nutritional deficiencies that can be alleviated with diet. Meanwhile, more than 1 in 10 Americans have now taken the newest weight-loss medications. On these drugs, patients can lose about 15% of their weight, but they must remain on the drugs for life — those who stop gain all of the weight back. Side effects are similar to the surgery. The drugs and the surgery work somewhat similarly by essentially quashing people's hunger and cravings. And though the surgery is more expensive at the outset — about $12,000 to $15,000 — it's cheaper in the long-term compared to drugs that cost about $1,000 a month. Both treatments are often, but not always, covered by insurance. With the surgery, 'You take someone who is 100 pounds overweight and their knees hurt and they have sleep apnea,' said Carter, 'and you do a one-hour intervention and a year later they've lost 100 pounds and their knees don't hurt and the sleep apnea is gone. It's like a butterfly coming out of a cocoon.' But bariatric surgery has never been a popular weight-loss option for those who need it most. Of all Americans who are eligible for surgery, only about 1% undergo the procedure. Surgeons and weight-loss experts say that's largely been due to misconceptions about the procedure and stigma around obesity. 'If you've been treating patients with obesity for decades, you always felt like, 'Yes, I have a great treatment, I can do these surgeries and do them safely, I believe in them whole-heartedly,'' said Dr. Dan Azagury, a Stanford University bariatric surgeon. 'But you were still limited in your capacity to treat patients.' Azagury took over Stanford's Lifestyle and Weight Management Center in February 2020, about a year before Ozempic, the first blockbuster weight-loss drug, blew up. Over the next 18 months, the number of patients on weight-loss medications jumped from 50 to 2,000. He said friends would often ask him if he would be out of a job soon. The drugs, though, have in some ways validated the surgical interventions, Azagury said. Weight loss has notoriously been a fraught topic in doctors offices, with patients feeling judged and doctors feeling frustrated by their lack of treatment options. 'A lot of times doctors would just say that you should eat less,' Azagury said. 'And I think patients intrinsically didn't see obesity as a medical condition,' he said. The success of recent weight-loss drugs, though, has made that conversation more palatable both to patients and providers, Azagury said. And he believes that is making some patients more amenable to a surgical option. There are, broadly, now three buckets for treating weight loss: diet and exercise, medication and surgery. The first option is likely best for people who don't have a lot of weight to lose and who are not facing any immediate complications related to their weight. They can manage their own treatment, or get a referral to a community or private weight-loss program. From there, patients with more serious obesity can decide if medication or surgery — or both — is the best option for them. Some people may be resistant to the idea of any surgical procedure and opt for medication. Others may decide that they would rather not deal with weekly injections for the rest of their life and prefer a one-time operation. Many patients, though, will end up with multiple interventions over their lifetime. They may start with medication and eventually decide they want a more permanent solution. Or they may get bariatric surgery and a few years later decide to start a medication if their weight is creeping back up. Mandy Hinz, 47, fought with her weight all her life, and it's only in the past two years that she finally felt like she had options. She had inquired about bariatric surgery about 20 years ago but was told she would need to lose 100 pounds before doctors would consider it safe. After that, she was up and down, peaking at about 415 pounds on her 5-foot, 3-inch frame. She started Ozempic in early 2023, and though the drug made her feel 'super sick,' she stuck with it and lost about 30 pounds. Around that time, Hinz, a Sacramento resident, was referred to the bariatric program at UCSF, and in October 2023, she finally got a gastric sleeve. She got down to about 200 pounds from the surgery, then started a different weight-loss drug and lost another 20 pounds. Though she's still obese for her height, Hinz said she's not interested in losing much more weight. 'I'm 180 and completely happy,' Hinz said. 'My journey has been absolutely amazing.' She noted that even with all of the tools at her disposal, losing the weight was never easy. And she has friends for whom even the newest therapies aren't solving all of their weight issues. But for Hinz, the weight-loss drugs finally unlocked a path that had never felt accessible to her. 'Being big my whole life, I missed out on a lot of stuff,' she said. Walking up and down stairs had become difficult, or spending a day on her feet at an amusement park. 'Now I can run up and down the stairs, I can walk around the amusement park the whole day. I went on my first hike a year and a half ago. It's like, let's go, let's do this.' Azagury said he's most thrilled for the patients — and their doctors — who have the most weight to lose, and especially those for whom a combination of medical and surgical therapies could be life-saving. 'The worst thing for a bariatric surgeon is when you get a patient in your clinic and it's too late — their condition is so bad that surgery is unsafe,' Azagury said. 'The conversation is, 'You have a condition I can treat, but I can't treat you.' It's the worst conversation. And I never have to have it anymore. Now I can tell them: 'I can't do surgery, but I have a good alternative for you.''


Business Insider
9 hours ago
- Business Insider
Hims & Hers Health (HIMS) Is About to Report Q2 Earnings. Here's What to Expect
Hims & Hers Health (HIMS) is scheduled to announce its results for the second quarter of 2025 after the market closes on Monday, August 4. HIMS stock has rallied 171% year-to-date, as investors are confident about the prospects of the health and wellness company, including its continued international expansion. However, Wall Street is cautious on Hims & Hers Health stock due to certain concerns, including the recent fallout with Novo Nordisk (NVO) over the alleged illegal sale of compounded versions of the weight loss drug Wegovy. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Wall Street expects HIMS to report earnings per share (EPS) of $0.15, reflecting a 150% year-over-year growth. Sales are expected to grow by about 75% to $551.67 million. TD Cowen Analyst's Views Ahead of Hims & Hers Health's Q2 Earnings Heading into Q2 results, TD Cowen analyst Jonna Kim reiterated a Hold rating on HIMS stock but raised the price target to $43 from $38. The 4-star analyst expects the company to deliver an EPS beat. Kim expects Q2 sales growth to come above the Street's estimate. However, Kim noted that the latest data points indicate a deceleration in trends, which could lead to management maintaining the full-year outlook. The analyst remains neutral on HIMS stock as comparisons get tougher in the second half of 2025, with uncertainty around compounded GLP-1s. Nonetheless, Kim believes that international growth could be meaningful to HIMS' sales starting in Fiscal 2026. Kim noted the rally in HIMS stock and stated that he sees a lack of substantial upside in the second half of 2025, as the company 'laps outsized growth' from last year. AI Analyst Is Bullish on HIMS Stock Ahead of Q2 Print Interestingly, TipRanks' AI stock analyst has assigned an Outperform rating to HIMS stock with a price target of $73, indicating 16.7% downside risk. Based on TipRanks' AI analysis, HIMS stock reflects significant strength in financial performance and strategic growth plans, supported by favorable earnings call insights. However, high valuation and technical indicators suggest caution, especially given potential overbought conditions and margin pressures. Options Traders Anticipate Major Move on Hims & Hers Health's Q2 Earnings Using TipRanks' Options tool, we can see what options traders are expecting from the stock immediately after its earnings report. The expected earnings move is determined by calculating the at-the-money straddle of the options closest to expiration after the earnings announcement. If this sounds complicated, don't worry, the Options tool does this for you. Indeed, it currently says that options traders are expecting about a 17.3% move in either direction in HIMS stock in reaction to Q2 results. Is HIMS Stock a Good Buy? Currently, Wall Street has a Hold consensus rating on Hims & Hers Health stock based on one Buy, seven Holds, and two Sell recommendations. The average HIMS stock price target of $42.33 indicates 32.3% downside risk from current levels.
Yahoo
15 hours ago
- Yahoo
Americans' becoming more aware of GLP-1 drugs like Ozempic, Wegovy: Survey
The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped significantly in the last few years, a new survey shows. The YouGov poll, released Friday, shows that at least 80 percent of respondents have heard at least 'a little bit' about semaglutide, a medication used to treat Type 2 diabetes that also helps a user to shed weight. In March 2023, only 60 percent of Americans were aware of the drug. A year later, in March 2024, that number had jumped to 70 percent, the pollster noted. The latest survey also shows that the share of those who have heard 'a lot' about the medication has nearly doubled since 2023, increasing to 41 percent from 23 percent. Just 36 percent of respondents say they know someone who has taken semaglutide. Around 14 percent listed a family member took the medicine, 16 percent named a friend, 11 percent identified an acquaintance and 7 percent said they had taken it themselves, according to the poll. Several also noted they knew a user in more than one category. Women are more likely than men, 43 percent to 29 percent, to know someone — including themselves — who has taken a GLP-1 agonist drug, per the survey. The weight loss medications — including Wegovy, Ozempic, Zepbound and others — have been available since 2005 but have only in the past few years been used to treat obesity. The drugs work by mimicking a hormone in the body — glucagon-like peptide-1 — that stimulates insulin secretion and reduces appetite. Possible side effects of taking the medication include nausea, diarrhea, vomiting, and constipation. While semaglutide is currently only prescribed for weight loss or treating diabetes, early research is pointing to possible benefits for a host of other issues, including treatment for addiction, neurodegenerative diseases and conditions that affect the heart, kidney or liver. The latest survey found that roughly a quarter of respondents said they would be 'very' or 'somewhat' interested in taking the medication as a weight loss treatment. About a third of Americans have either taken the drug or said they would be interested in trying it. On the other side, about 17 percent said they were 'not very' interested in the medication and 45 percent signaled they were not at all interested. A separate poll from last September found that around a quarter of adults in the U.S. would consider using weight loss medications without consulting their doctor. The YouGov analysis is based on an online survey conducted from May 22-25 among 1,109 adults in the U.S. The margin of error for the full sample is 4 percentage points. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.